Ingredient or product comparison
GHK-Cu and TB-500 Stack: Research Protocol Comparison
Biomedicine & Pharmacotherapy 2020 Diabetic mouse excisional wounds 500 µg topical 200 µg topical Once daily × 14 days Wound closure % at day 14 89% closure (combination) vs 67% (GHK-Cu alone) vs 71% (TB-500 alone) vs 48% (saline) Int J Mol Sci 2021 Human fibr
This source-based comparison does not add ratings or recommend a winner.
- Biomedicine & Pharmacotherapy 2020
- Diabetic mouse excisional wounds
- 500 µg topical
- 200 µg topical
- Once daily × 14 days
- Wound closure % at day 14
- 89% closure (combination) vs 67% (GHK-Cu alone) vs 71% (TB-500 alone) vs 48% (saline)
- Int J Mol Sci 2021
- Human fibroblast collagen gel contraction
- 10 µM in media
- 50 nM in media
- Continuous exposure × 7 days
- Gel contraction %
- 64% contraction (combination) vs 32% (GHK-Cu) vs 19% (TB-500) vs baseline
- J Invest Dermatol 2019
- Keratinocyte scratch assay
- 5 µM in media
- 100 nM in media
- Continuous exposure × 48 hours
- Migration velocity (µm/hr)
- 31 µm/hr (combination) vs 18 µm/hr (TB-500) vs 12 µm/hr (GHK-Cu) vs 12 µm/hr (control)
- Professional Assessment
- All three studies used mechanistically distinct endpoints (closure, contraction, migration) yet showed consistent synergistic effects in the 40–60% improvement range when combining GHK-Cu and TB-500 compared to individual peptides. The dosing across models converged on GHK-Cu at 1–10 µM and TB-500 at 10–100 nM. Concentrations that align with receptor binding affinities for their respective targets.